123
Participants
Start Date
April 30, 2008
Primary Completion Date
January 31, 2013
Study Completion Date
February 28, 2013
TAK-700
"Phase 1 portion of study:~TAK-700 dose escalation. Tablets administered orally, twice daily until disease progression or occurrence of an unacceptable adverse event.~Phase 2 portion of study:~Patients will receive one of 4 treatments:~* TAK-700 at 300 mg twice/day~* TAK-700 at 400 mg and 5 mg prednisone twice/day~* TAK-700 at 600 mg and 5 mg prednisone twice/day~* TAK-700 at 600 mg once/day in the morning"
Cleveland Clinic, Cleveland
Northwestern University Medical Center, Chicago
University of Chicago, Chicago
University of Southern California, Los Angeles
USC Westside Prostate Cancer Center, Beverly Hills
The Angeles Clinic and Research Institute, Los Angeles
USC Norris Comprehensive Cancer Center, Los Angeles
South Florida Medical Research, Aventura
Florida Cancer Specialists, Fort Myers
University of Chicago Comprehensive Cancer Center, Chicago
University of Chicago Pharmacy, Chicago
Evanston Hospital, Evanston
Kellogg Pharmacy - Evanston Hospital, Evanston
NorthShore University HealthSystem, Evanston
Kellogg Cancer Care Center, Glenview
Hematology/Oncology Associates of Central New York, East Syracuse
Gabrail Cancer Center, Canton
Taussig Cancer Institute, Cleveland
Tennessee Oncology, Nashville
Lead Sponsor
Millennium Pharmaceuticals, Inc.
INDUSTRY